HeartWare International Inc  

(Public, NASDAQ:HTWR)   Watch this stock  
Find more results for htwr
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 69.05 - 95.59
Open     -
Vol / Avg. 0.00/310,252.00
Mkt cap 1.29B
P/E     -
Div/yield     -
EPS -0.85
Shares 17.26M
Beta -0.16
Inst. own 112%
Jul 29, 2015
Q2 2015 HeartWare International Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 11, 2015
HeartWare International Inc at Goldman Sachs Healthcare Conference - 11:00AM EDT - Add to calendar
Jun 4, 2015
HeartWare International Inc Annual Shareholders Meeting - 8:00AM EDT - Add to calendar
May 14, 2015
HeartWare International Inc at Bank of America Merrill Lynch Health Care Conference
Apr 30, 2015
Q1 2015 HeartWare International Inc Earnings Release
Apr 30, 2015
Q1 2015 HeartWare International Inc Earnings Call - Webcast
Apr 16, 2015
HeartWare Investor Meeting Breakout Session - Webcast
Apr 16, 2015
HeartWare Lunch Symposium: Deeper Dive into HeartWare Clinical and Real-world Results - Webcast
Mar 10, 2015
HeartWare International Inc at Barclays Healthcare Conference - Webcast
Mar 3, 2015
HeartWare International Inc at Raymond James Institutional Investors Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -20.76% -6.96%
Operating margin -10.45% -0.04%
EBITD margin - -5.37%
Return on average assets -13.92% -4.54%
Return on average equity -28.54% -9.51%
Employees 585 -
CDP Score - -


500 Old Connecticut Path
United States - Map
+1-508-7390873 (Phone)
+1-508-7390948 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Heartware International, Inc. (HeartWare) develops and manufactures small implantable heart pumps or ventricular assist devices to treat patients suffering from advanced heart failure. The HeartWare Ventricular Assist System (the HVAD System), which includes a ventricular assist device (VAD), or blood pump, patient accessories and surgical tools, is designed to provide circulatory support for patients in the advanced stage of heart failure. The core of the HVAD System is a continuous flow blood pump, the HVAD Pump, which is a full-output device capable of pumping up to 10 liters of blood per minute. The HVAD System is designed to be implanted adjacent to the heart, avoiding the abdominal surgery generally required to implant similar devices.

Officers and directors

C. Raymond Larkin Jr. Independent Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Douglas Evan Godshall M.B.A. President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Seth L. Harrison M.D. Deputy Chairman of the Board
Age: 54
Bio & Compensation  - Reuters
Peter F. McAree Chief Financial Officer, Senior Vice President, Treasurer
Age: 50
Bio & Compensation  - Reuters
Jeffrey A. LaRose Executive Vice President, Chief Scientific Officer
Age: 52
Bio & Compensation  - Reuters
Lawrence Knopf Senior Vice President, General Counsel, Secretary
Age: 53
Bio & Compensation  - Reuters
James Schuermann Senior Vice President - Sales and Marketing
Age: 46
Bio & Compensation  - Reuters
Mark Strong Senior Vice President, Research and Development and Quality Assurance
Age: 43
Bio & Compensation  - Reuters
Robert Yocher Senior Vice President, Regulatory Affairs
Age: 63
Bio & Compensation  - Reuters
Katrin Leadley M.D. Chief Medical Officer
Age: 52
Bio & Compensation  - Reuters